1. Aggleton, P., & Parker, R. (2015). Moving beyond biomedicalization in the HIV response: Implications for community involvement and community leadership among men who have sex with men and transgender people. American Journal of Public Health, 105(8), 1552–1558. https://doi.org/10.2105/AJPH.2015.302614.
2. Alcorn, K. (2005). Thai tenofovir trial runs into trouble after ethics protests from drug users. NAM aidsmap. Retrieved March 9, 2020, from https://www.aidsmap.com/news/mar-2005/thai-tenofovir-trial-runs-trouble-after-ethics-protests-drug-users.
3. Allen, S. T., O’Rourke, A., White, R. H., Smith, K. C., Weir, B., Lucas, G. M., Sherman, S., & Grieb, S. M. (2020). Barriers and facilitators to PrEP use among people who inject drugs in rural Appalachia: A qualitative study. AIDS and Behavior, 24(6), 1942–1950. https://doi.org/10.1007/s10461-019-02767-3.
4. Auerbach, J. D., & Hoppe, T. A. (2015). Beyond “getting drugs into bodies”: Social science perspectives on pre-exposure prophylaxis for HIV. Journal of the International AIDS Society, 18(Supplement 3), 19983.
5. Ayala, G., Chang, J., Matheson, R., Sprague, L., & Thomas, R. M. (2017). Reconsidering primary prevention of HIV: New steps forward in the global response. New York: The Global Forum on MSM & HIV.